Capital For R&D And Product ExpansionProceeds from the recent equity offering improve liquidity and fund expanded R&D for the Dream Sight camera and other features, enabling additional subscription offerings and broader international rollouts.
Regulatory MoatOwlet's position as an FDA-cleared wearable infant pulse oximeter combined with CE regulatory approvals creates a meaningful competitive moat that supports premium positioning and international distributor relationships.
Subscription GrowthStrong early adoption of Owlet 360, with over 90,000 subscribers and recent market rollouts, is positioned to drive recurring, higher-margin subscription revenue and extend customer lifetime value.